CIC
NVO

Carnegie Investment Counsel’s Novo Nordisk NVO Stock Holding History

Carnegie Investment Counsel’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.16M Sell
170,256
-7,773
-4% -$334K 0.16% 134
2026
Q1 		$6.54M Sell
178,029
-67,020
-27% -$3.18M 0.13% 160
2025
Q4 		$12.5M Sell
245,049
-27,820
-10% -$1.42M 0.23% 116
2025
Q3 		$15.1M Sell
272,869
-16,640
-6% -$974K 0.29% 100
2025
Q2 		$20M Buy
289,509
+17,034
+6% +$1.16M 0.4% 71
2025
Q1 		$17.4M Buy
272,475
+73,930
+37% +$6.11M 0.41% 73
2024
Q4 		$17.1M Sell
198,545
-14,949
-7% -$1.62M 0.49% 64
2024
Q3 		$25.4M Sell
213,494
-1,072
-0.5% -$143K 0.75% 37
2024
Q2 		$30.6M Buy
214,566
+2,262
+1% +$300K 0.95% 21
2024
Q1 		$27.3M Buy
212,304
+5,952
+3% +$709K 0.85% 26
2023
Q4 		$21.3M Buy
206,352
+6,040
+3% +$597K 0.73% 42
2023
Q3 		$18.2M Buy
200,312
+19,970
+11% +$1.76M 0.7% 42
2023
Q2 		$14.6M Buy
180,342
+2,316
+1% +$189K 0.54% 53
2023
Q1 		$14.2M Buy
178,026
+11,426
+7% +$810K 0.56% 52
2022
Q4 		$11.3M Buy
166,600
+45,312
+37% +$2.66M 0.48% 62
2022
Q3 		$6.04M Sell
121,288
-1,596
-1% -$85.5K 0.29% 96
2022
Q2 		$6.85M Sell
122,884
-3,668
-3% -$204K 0.31% 94
2022
Q1 		$7.03M Sell
126,552
-4,166
-3% -$214K 0.26% 107
2021
Q4 		$7.32M Sell
130,718
-2,320
-2% -$126K 0.24% 112
2021
Q3 		$6.39M Buy
133,038
+812
+0.6% +$39.3K 0.24% 112
2021
Q2 		$5.54M Sell
132,226
-2,220
-2% -$86.1K 0.21% 119
2021
Q1 		$4.53M Buy
134,446
+880
+0.7% +$31.3K 0.19% 127
2020
Q4 		$4.67M Sell
133,566
-1,228
-0.9% -$42.4K 0.21% 118
2020
Q3 		$4.68M Sell
134,794
-1,450
-1% -$48.3K 0.24% 112
2020
Q2 		$4.46M Sell
136,244
-1,204
-0.9% -$38.4K 0.26% 107
2020
Q1 		$4.14M Sell
137,448
-2,500
-2% -$74.4K 0.29% 98
2019
Q4 		$4.05M Buy
139,948
+7,494
+6% +$208K 0.23% 117
2019
Q3 		$3.42M Sell
132,454
-14,784
-10% -$374K 0.22% 121
2019
Q2 		$3.76M Sell
147,238
-18,430
-11% -$455K 0.24% 111
2019
Q1 		$4.33M Sell
165,668
-11,668
-7% -$287K 0.3% 100
2018
Q4 		$4.08M Sell
177,336
-41,256
-19% -$917K 0.38% 82
2018
Q3 		$4.84M Buy
218,592
+11,114
+5% +$271K 0.4% 76
2018
Q2 		$5.01M Sell
207,478
-8,836
-4% -$210K 0.38% 80
2018
Q1 		$5.31M Sell
216,314
-10,810
-5% -$284K 0.45% 71
2017
Q4 		$5.67M Sell
227,124
-6,396
-3% -$163K 0.5% 61
2017
Q3 		$5.86M Sell
233,520
-12,218
-5% -$276K 0.69% 37
2017
Q2 		$5.2M Sell
245,738
-11,014
-4% -$222K 0.63% 47
2017
Q1 		$5.18M Sell
256,752
-56,354
-18% -$981K 0.64% 49
2016
Q4 		$5.79M Sell
313,106
-18,332
-6% -$332K 0.77% 42
2016
Q3 		$6.67M Buy
331,438
+17,786
+6% +$441K 0.96% 31
2016
Q2 		$8.84M Sell
313,652
-3,900
-1% -$107K 1.25% 15
2016
Q1 		$8.6M Buy
317,552
+5,150
+2% +$138K 1.32% 11
2015
Q4 		$8.71M Sell
312,402
-390
-0.1% -$10.8K 1.51% 7
2015
Q3 		$8.76M Buy
312,792
+12,024
+4% +$340K 1.5% 8
2015
Q2 		$8.23M Sell
300,768
-3,592
-1% -$101K 1.44% 10
2015
Q1 		$8.43M Buy
304,360
+1,460
+0.5% +$33.6K 1.45% 11
2014
Q4 		$6.49M Buy
302,900
+22,220
+8% +$496K 1.22% 19
2014
Q3 		$6.68M Sell
280,680
-1,794
-0.6% -$41.3K 1.33% 10
2014
Q2 		$6.52M Buy
282,474
+6,974
+3% +$154K 1.48% 11
2014
Q1 		$6.29M Sell
275,500
-11,500
-4% -$245K 1.66% 8
2013
Q4 		$5.3M Buy
287,000
+44,900
+19% +$782K 1.42% 13
2013
Q3 		$4.1M Buy
242,100
+15,410
+7% +$259K 1.26% 26
2013
Q2 		$3.51M Buy
+226,690
New +$3.77M 1.16% 30

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Carnegie Investment Counsel's NVO Position: Q2 2026 in Review

Carnegie Investment Counsel reduced its Novo Nordisk (NVO) stake by 4.4% in Q2 2026, selling an estimated $334K and leaving 170,256 shares worth $8.16M. The position accounts for 0.16% of the portfolio, ranked #134.

Carnegie Investment Counsel first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $30.6M in Q2 2024. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Carnegie Investment Counsel held 170,256 shares of Novo Nordisk worth $8.16M as of Q2 2026.
  • Carnegie Investment Counsel sold 7,773 Novo Nordisk shares in Q2 2026, an estimated $334K.
  • Novo Nordisk made up 0.16% of Carnegie Investment Counsel's portfolio in Q2 2026, its #134 holding.
  • Carnegie Investment Counsel first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Carnegie Investment Counsel's Novo Nordisk position peaked at $30.6M in Q2 2024.
  • 580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.